OBJECTIVES: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are typically the first injectable glucose-lowering agent (GLA) recommended for T2D. Observational studies are important for understanding their use in clinical practice.

METHODS: TROPHIES is 24-month, prospective, observational study conducted in France, Germany and Italy on T2D patients initiating their first injectable GLA with once‑weekly dulaglutide (DU) or once-daily liraglutide (LIRA). Patient characteristics and outcome parameters were analyzed at 6-months. Treatment patterns at day30 and 90 were also analyzed.

RESULTS: 1113 DU and 1042 LIRA patients were eligible for analysis. The mean(SD) HbA1c was 8.2(1.2)% and 8.3(1.3)% at baseline for DU and LIRA, respectively, and 6.9(1.1)% and 7.0(1.1)% at 6-months (mean absolute HbA1c -1.3(1.4)% change). 35.9% DU and 31.0% LIRA patients reached their individual targets set by the physician at baseline. The baseline mean weight for DU and LIRA was 95.8(21.4)kg and 97.4(21.5)kg, and mean weight change was -3.4(5.2)kg and -3.0(5.1)kg, respectively. At baseline, 15% DU patients started 0.75mg and 85% started 1.5mg. Between days 1-90, the max DU dose was 1.5mg for 90% patients. At day90, 83% patients were receiving 1.5mg DU. At baseline, 81% patients started at 0.6mg LIRA; 17% started at 1.2mg; and 2% started at 1.8mg. Between days 1-90, the max LIRA dose was 0.6mg for 36% patients; 1.2 mg for 51%; 1.8mg for 13%. By day90, 31% LIRA patients increased their dose from 0.6mg to 1.2mg; 9% changed from 0.6mg to eventually reach 1.8mg. By day30, in both arms, around 2% of patients added and 10% of patients stopped at least one oral GLA.

CONCLUSIONS: The results show HbA1c and weight reductions in line with known clinical trial results. The majority of DU patients received 1.5mg DU. More LIRA patients received 1.2mg or 0.6mg than 1.8mg LIRA.